What differentiates Vivaglobin® from other current treatments for PI?
Vivaglobin® is the first and only subcutaneous (under the skin) immunoglobulin therapy available for PI patients in the U.S. Currently, the most common method of administering Ig in the U.S. is intravenously, or infusing into the vein. However, intravenous administration may not be optimal for all patients. This product was designed to offer PI patients an alternative to intravenous immunoglobulin therapy, including, with a physician’s training and approval, the option of self-administration.
